Search

Your search keyword '"Matthews VB"' showing total 104 results

Search Constraints

Start Over You searched for: Author "Matthews VB" Remove constraint Author: "Matthews VB"
104 results on '"Matthews VB"'

Search Results

1. May Measurement Month 2017: an analysis of blood pressure screening results from Australia-South-East Asia and Australasia

2. Shining LIGHT on the metabolic role of the cytokine TNFSF14 and the implications on hepatic IL-6 production

3. Erratum to: Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinase.

4. Erratum to: Brain-derived neurotrophic factor is produced by skeletal muscle cells in response to contraction and enhances fat oxidation via activation of AMP-activated protein kinase

5. Interleukin-6 attenuates insulin-mediated increases in endothelial cell signaling but augments skeletal muscle insulin action via differential effects on tumor necrosis factor-alpha expression.

6. Interleukin-6 attenuates insulin-mediated increases in endothelial cell signaling but augments skeletal muscle insulin action via differential effects on tumor necrosis factor-alpha expression.

7. A locus affecting immunoglobulin isotype selection (Igis1) maps to the MHC region in C57BL, BALB/c and NOD mice.

8. Sympathetic Activation Promotes Sodium Glucose Co-Transporter-1 Protein Expression in Rodent Skeletal Muscle.

9. S-Methyl Cysteine Sulfoxide Does Not Ameliorate Weight Gain or Hyperlipidemia in Mice Fed a High-Fat Diet.

10. SGLT1/2 inhibition improves glycemic control and multi-organ protection in type 1 diabetes.

11. Multi-organ denervation: a novel approach to combat cardiometabolic disease.

12. Comparing and Contrasting the Effects of the SGLT Inhibitors Canagliflozin and Empagliflozin on the Progression of Retinopathy.

13. Determining the Role of SGLT2 Inhibition with Dapagliflozin in the Development of Diabetic Retinopathy.

14. Evaluation of Circulating Platelet Extracellular Vesicles and Hypertension Mediated Organ Damage.

15. Platelet-derived extracellular vesicles correlate with therapy-induced nocturnal blood pressure changes.

16. Association of Circulating Platelet Extracellular Vesicles and Pulse Wave Velocity with Cardiovascular Risk Estimation.

17. Retinal Capillary Damage Is Already Evident in Patients With Hypertension and Prediabetes and Associated With HbA1c Levels in the Nondiabetic Range.

18. Circulating platelet-derived extracellular vesicles correlate with night-time blood pressure and vascular organ damage and may represent an integrative biomarker of vascular health.

19. Determining the role of SGLT2 inhibition with Empagliflozin in the development of diabetic retinopathy.

20. Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition.

21. Interaction between sodium-glucose co-transporter 2 and the sympathetic nervous system.

22. The Effect of SGLT2 Inhibition on Diabetic Kidney Disease in a Model of Diabetic Retinopathy.

23. A standarized protocol for evaluation of large extracellular vesicles using the attune™ NXT system.

24. Bexagliflozin for type 2 diabetes: an overview of the data.

25. TNFSF14-Derived Molecules as a Novel Treatment for Obesity and Type 2 Diabetes.

26. Role of the sympathetic nervous system in cardiometabolic control: implications for targeted multiorgan neuromodulation approaches.

27. Metabolic dysfunction induced by a high-fat diet modulates hematopoietic stem and myeloid progenitor cells in brown adipose tissue of mice.

28. Increased pulse wave velocity in patients with an orthostatic blood pressure rise independent of other cardiovascular risk factors.

29. Role of Microparticles in Cardiovascular Disease: Implications for Endothelial Dysfunction, Thrombosis, and Inflammation.

30. Combined renal and common hepatic artery denervation as a novel approach to reduce cardiometabolic risk: technical approach, feasibility and safety in a pre-clinical model.

31. Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD)-A Condition Associated with Heightened Sympathetic Activation.

33. Nocturnal hypertension: a common phenotype in a tertiary clinical setting associated with increased arterial stiffness and central blood pressure.

34. Microvascular changes at different stages of chronic kidney disease.

35. Retinal capillary rarefaction is associated with arterial and kidney damage in hypertension.

36. Supine blood pressure-A clinically relevant determinant of vascular target organ damage in hypertensive patients.

37. SGLT2 Inhibitor-Induced Sympathoexcitation in White Adipose Tissue: A Novel Mechanism for Beiging.

38. Reduced mitochondrial translation prevents diet-induced metabolic dysfunction but not inflammation.

39. The Influence of Hypertensive Therapies on Circulating Factors: Clinical Implications for SCFAs, FGF21, TNFSF14 and TNF-α.

40. Renal denervation as a synergistic tool for the treatment of polymorphic ventricular ectopic beats: A case report.

41. An evaluation of empagliflozin and it's applicability to hypertension as a therapeutic option.

42. Sodium glucose co-transporter 2 inhibition reduces succinate levels in diabetic mice.

43. The Schlager mouse as a model of altered retinal phenotype.

44. Does sympathetic hyperactivity adversely impact on the effect of pre-ablation bariatric surgery and atrial fibrillation recurrence in morbidly obese patients undergoing atrial fibrillation ablation?

45. Low-dose UV radiation before running wheel access activates brown adipose tissue.

46. SGLT2 Inhibitor-Induced Sympathoinhibition: A Novel Mechanism for Cardiorenal Protection.

47. Sympathetic Activation in Hypertensive Chronic Kidney Disease - A Stimulus for Cardiac Arrhythmias and Sudden Cardiac Death?

49. Effects of sympathetic modulation in metabolic disease.

50. New Molecules for Treating Resistant Hypertension: a Clinical Perspective.

Catalog

Books, media, physical & digital resources